Understanding the burden of interstitial lung disease post-COVID-19: The UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)

UKILD-Long COVID; Jim M. Wild; Joanna C. Porter; Philip L. Molyneaux; Peter M. George; Iain Stewart; Richard James Allen; Raminder Aul; John Kenneth Baillie; Shaney L. Barratt; Paul Beirne; Stephen M. Bianchi; John F. Blaikley; Jonathan Brooke; Nazia Chaudhuri; Guilhem Collier; Emma K. Denneny; Annemarie Docherty; Laura Fabbri; Michael A. Gibbons; Fergus V. Gleeson; Bibek Gooptu; Ian P. Hall; Neil A. Hanley; Melissa Heightman; Toby E. Hillman; Simon R. Johnson; Mark G. Jones; Fasihul Khan; Rod Lawson; Puja Mehta; Jane A. Mitchell; Manuela Platé; Krisnah Poinasamy; Jennifer K. Quint; Pilar Rivera-Ortega; Malcolm Semple; A. John Simpson; D. J.F. Smith; Mark Spears; Lisa G. Spencer; Stefan C. Stanel; David R. Thickett; A. A.Roger Thompson; Simon L.F. Walsh; Nicholas D. Weatherley; Mark Everard Weeks; Dan G. Wootton; Chris E. Brightling; Rachel C. Chambers; Ling Pei Ho; Joseph Jacob; Karen Piper Hanley; Louise V Wain; R Gisli Jenkins

doi:10.1136/bmjresp-2021-001049

Understanding the burden of interstitial lung disease post-COVID-19: The UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)

UKILD-Long COVID, Jim M. Wild, Joanna C. Porter, Philip L. Molyneaux, Peter M. George, Iain Stewart, Richard James Allen, Raminder Aul, John Kenneth Baillie, Shaney L. Barratt, Paul Beirne, Stephen M. Bianchi, John F. Blaikley, Jonathan Brooke, Nazia Chaudhuri, Guilhem Collier, Emma K. Denneny, Annemarie Docherty, Laura Fabbri, Michael A. GibbonsFergus V. Gleeson, Bibek Gooptu, Ian P. Hall, Neil A. Hanley, Melissa Heightman, Toby E. Hillman, Simon R. Johnson, Mark G. Jones, Fasihul Khan, Rod Lawson, Puja Mehta, Jane A. Mitchell, Manuela Platé, Krisnah Poinasamy, Jennifer K. Quint, Pilar Rivera-Ortega, Malcolm Semple, A. John Simpson, D. J.F. Smith, Mark Spears, Lisa G. Spencer, Stefan C. Stanel, David R. Thickett, A. A.Roger Thompson, Simon L.F. Walsh, Nicholas D. Weatherley, Mark Everard Weeks, Dan G. Wootton, Chris E. Brightling, Rachel C. Chambers, Ling Pei Ho, Joseph Jacob, Karen Piper Hanley, Louise V Wain, R Gisli Jenkins

Research output: Contribution to journal › Article › peer-review

21 Citations (Scopus)

11 Downloads (Pure)

Abstract

Introduction The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness and fatigue whether hospitalised or not. Early data suggest potentially severe long-term consequence of COVID-19 is development of long COVID-19-related interstitial lung disease (LC-ILD). Methods and analysis The UK Interstitial Lung Disease Consortium (UKILD) will undertake longitudinal observational studies of patients with suspected ILD following COVID-19. The primary objective is to determine ILD prevalence at 12 months following infection and whether clinically severe infection correlates with severity of ILD. Secondary objectives will determine the clinical, genetic, epigenetic and biochemical factors that determine the trajectory of recovery or progression of ILD. Data will be obtained through linkage to the Post-Hospitalisation COVID platform study and community studies. Additional substudies will conduct deep phenotyping. The Xenon MRI investigation of Alveolar dysfunction Substudy will conduct longitudinal xenon alveolar gas transfer and proton perfusion MRI. The POST COVID-19 interstitial lung DiseasE substudy will conduct clinically indicated bronchoalveolar lavage with matched whole blood sampling. Assessments include exploratory single cell RNA and lung microbiomics analysis, gene expression and epigenetic assessment. Ethics and dissemination All contributing studies have been granted appropriate ethical approvals. Results from this study will be disseminated through peer-reviewed journals. Conclusion This study will ensure the extent and consequences of LC-ILD are established and enable strategies to mitigate progression of LC-ILD.

Original language	English
Article number	e001049
Number of pages	10
Journal	BMJ Open Respiratory Research
Volume	8
Issue number	1
DOIs	https://doi.org/10.1136/bmjresp-2021-001049
Publication status	Published - 23 Sept 2021

Bibliographical note

Funding Information:
The UKILD-Long COVID study is a prospective multi-centre observational cohort study that will be managed through the Imperial College National Heart and Lung Institute and funded by the UKRI Medical Research Council and an NIHR professorship (RGJ). The primary study aims to define the prevalence and risk factors for LC-ILD using data from 10 000 stratified patients, collected from the UK’s national PHOSP for COVID platform study, together with 2000 non-hospitalised patients referred for assessment up to 3 months for investigation of persistent respiratory symptoms post-COVID-19, such as breathlessness and cough (figure 1A). These patients will be recruited from Long COVID clinics or community Post-COVID-19 clinical trials (REACT Long COVID Study19). We will assess the clinical and genetic risk factors for post-COVID-19 ILD and radiological classification, as well as the trajectory and pathogenic mechanisms of progression following acute COVID with longitudinal analysis of biomarkers and the undertaking of two substudies (figure 1B). 1. Up to 80 participants will undergo detailed longitudi-nal xenon and proton MRI coupled with measures of flow-mediated endothelial function in the microvascu-lature measured by EndoPat. 2. Up to 50 participants will undergo bronchoscopy with bronchoalveolar lavage (BAL) for single cell and/or bulk RNA sequencing (RNA-seq), with matched flow cytometry analysis, as well as microbiome analysis.

Funding The collaborative research programme entitled, The UK Interstitial Lung Disease-Long COVID-19 study (UKILD-Long COVID): understanding the burden of Interstitial Lung Disease in Long COVID is funded by UK Research and Innovation MRC research grant award (grant reference MR/W006111/1). The collaborative research programme entitled PHOSP-COVID Posthospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes is jointly funded by UK Research and Innovation and National Institute of Health Research (grant references: MR/V027859/1 and COV0319 and ISRCTN number 10980107). In addition, PM is supported by MRC—GlaxoSmithKline GSK Experimental Medicine and co-funding NIHR University College London Hospitals Biomedical Research Centre. JB is supported by MRC transition award (MR/ T032529/1). BG is funded by MRC-UK, the British Lung Foundation, The Alpha-1 Foundation and supported by the NIHR Leicester Biomedical Research Centre. IPH is supported by an NIHR Senior Investigator Award. SRJ is supported by Nottingham NIHR BRC. PLM is supported by an Action for Pulmonary Fibrosis Mike Bray fellowship. AART is supported by a British Heart Foundation Intermediate Clinical Fellowship (FS/18/13/3328). L-PH is supported by the NIHR Oxford Biomedical Research Centre. JJ is supported by a Wellcome Trust Clinical Research Career Development Fellowship (209553/Z/17/Z) and the NIHR UCLH Biomedical Research Centre, UK. LW holds a GSK/British Lung Foundation Chair in Respiratory Research (C17-1). The research was partially supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre. RGJ is supported by an NIHR Research Professorship (RP-2017-08-ST2-014). AJS is a National Institute for Health Research (NIHR) Senior Investigator. Disclaimer The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Competing interests None declared.

Keywords

bronchoscopy
COVID-19
interstitial fibrosis

ASJC Scopus subject areas

Pulmonary and Respiratory Medicine

Access to Document

10.1136/bmjresp-2021-001049Licence: Creative Commons: Attribution (CC BY)

WildJ2021UnderstandingFinal published version, 811 KBLicence: Creative Commons: Attribution (CC BY)

Post-hospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes (PHOSP-COVID)
Parekh, D., Sapey, E., Richter, A., Wraith, D. & Lord, J.
DEPARTMENT OF HEALTH & SOCIAL CARE
30/07/20 → 31/03/26
Project: Other Government Departments

Cite this

UKILD-Long COVID, Wild, J. M., Porter, J. C., Molyneaux, P. L., George, P. M., Stewart, I., Allen, R. J., Aul, R., Baillie, J. K., Barratt, S. L., Beirne, P., Bianchi, S. M., Blaikley, J. F., Brooke, J., Chaudhuri, N., Collier, G., Denneny, E. K., Docherty, A., Fabbri, L., ... Jenkins, R. G. (2021). Understanding the burden of interstitial lung disease post-COVID-19: The UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID). BMJ Open Respiratory Research, 8(1), Article e001049. https://doi.org/10.1136/bmjresp-2021-001049

@article{7d9184fad0a74e68a0f6258f31050f86,

title = "Understanding the burden of interstitial lung disease post-COVID-19: The UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)",

abstract = "Introduction The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness and fatigue whether hospitalised or not. Early data suggest potentially severe long-term consequence of COVID-19 is development of long COVID-19-related interstitial lung disease (LC-ILD). Methods and analysis The UK Interstitial Lung Disease Consortium (UKILD) will undertake longitudinal observational studies of patients with suspected ILD following COVID-19. The primary objective is to determine ILD prevalence at 12 months following infection and whether clinically severe infection correlates with severity of ILD. Secondary objectives will determine the clinical, genetic, epigenetic and biochemical factors that determine the trajectory of recovery or progression of ILD. Data will be obtained through linkage to the Post-Hospitalisation COVID platform study and community studies. Additional substudies will conduct deep phenotyping. The Xenon MRI investigation of Alveolar dysfunction Substudy will conduct longitudinal xenon alveolar gas transfer and proton perfusion MRI. The POST COVID-19 interstitial lung DiseasE substudy will conduct clinically indicated bronchoalveolar lavage with matched whole blood sampling. Assessments include exploratory single cell RNA and lung microbiomics analysis, gene expression and epigenetic assessment. Ethics and dissemination All contributing studies have been granted appropriate ethical approvals. Results from this study will be disseminated through peer-reviewed journals. Conclusion This study will ensure the extent and consequences of LC-ILD are established and enable strategies to mitigate progression of LC-ILD.",

keywords = "bronchoscopy, COVID-19, interstitial fibrosis",

author = "{UKILD-Long COVID} and Wild, {Jim M.} and Porter, {Joanna C.} and Molyneaux, {Philip L.} and George, {Peter M.} and Iain Stewart and Allen, {Richard James} and Raminder Aul and Baillie, {John Kenneth} and Barratt, {Shaney L.} and Paul Beirne and Bianchi, {Stephen M.} and Blaikley, {John F.} and Jonathan Brooke and Nazia Chaudhuri and Guilhem Collier and Denneny, {Emma K.} and Annemarie Docherty and Laura Fabbri and Gibbons, {Michael A.} and Gleeson, {Fergus V.} and Bibek Gooptu and Hall, {Ian P.} and Hanley, {Neil A.} and Melissa Heightman and Hillman, {Toby E.} and Johnson, {Simon R.} and Jones, {Mark G.} and Fasihul Khan and Rod Lawson and Puja Mehta and Mitchell, {Jane A.} and Manuela Plat{\'e} and Krisnah Poinasamy and Quint, {Jennifer K.} and Pilar Rivera-Ortega and Malcolm Semple and Simpson, {A. John} and Smith, {D. J.F.} and Mark Spears and Spencer, {Lisa G.} and Stanel, {Stefan C.} and Thickett, {David R.} and Thompson, {A. A.Roger} and Walsh, {Simon L.F.} and Weatherley, {Nicholas D.} and Weeks, {Mark Everard} and Wootton, {Dan G.} and Brightling, {Chris E.} and Chambers, {Rachel C.} and Ho, {Ling Pei} and Joseph Jacob and Hanley, {Karen Piper} and Wain, {Louise V} and Jenkins, {R Gisli}",

note = "Funding Information: The UKILD-Long COVID study is a prospective multi-centre observational cohort study that will be managed through the Imperial College National Heart and Lung Institute and funded by the UKRI Medical Research Council and an NIHR professorship (RGJ). The primary study aims to define the prevalence and risk factors for LC-ILD using data from 10 000 stratified patients, collected from the UK{\textquoteright}s national PHOSP for COVID platform study, together with 2000 non-hospitalised patients referred for assessment up to 3 months for investigation of persistent respiratory symptoms post-COVID-19, such as breathlessness and cough (figure 1A). These patients will be recruited from Long COVID clinics or community Post-COVID-19 clinical trials (REACT Long COVID Study19). We will assess the clinical and genetic risk factors for post-COVID-19 ILD and radiological classification, as well as the trajectory and pathogenic mechanisms of progression following acute COVID with longitudinal analysis of biomarkers and the undertaking of two substudies (figure 1B). 1. Up to 80 participants will undergo detailed longitudi-nal xenon and proton MRI coupled with measures of flow-mediated endothelial function in the microvascu-lature measured by EndoPat. 2. Up to 50 participants will undergo bronchoscopy with bronchoalveolar lavage (BAL) for single cell and/or bulk RNA sequencing (RNA-seq), with matched flow cytometry analysis, as well as microbiome analysis. Funding The collaborative research programme entitled, The UK Interstitial Lung Disease-Long COVID-19 study (UKILD-Long COVID): understanding the burden of Interstitial Lung Disease in Long COVID is funded by UK Research and Innovation MRC research grant award (grant reference MR/W006111/1). The collaborative research programme entitled PHOSP-COVID Posthospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes is jointly funded by UK Research and Innovation and National Institute of Health Research (grant references: MR/V027859/1 and COV0319 and ISRCTN number 10980107). In addition, PM is supported by MRC—GlaxoSmithKline GSK Experimental Medicine and co-funding NIHR University College London Hospitals Biomedical Research Centre. JB is supported by MRC transition award (MR/ T032529/1). BG is funded by MRC-UK, the British Lung Foundation, The Alpha-1 Foundation and supported by the NIHR Leicester Biomedical Research Centre. IPH is supported by an NIHR Senior Investigator Award. SRJ is supported by Nottingham NIHR BRC. PLM is supported by an Action for Pulmonary Fibrosis Mike Bray fellowship. AART is supported by a British Heart Foundation Intermediate Clinical Fellowship (FS/18/13/3328). L-PH is supported by the NIHR Oxford Biomedical Research Centre. JJ is supported by a Wellcome Trust Clinical Research Career Development Fellowship (209553/Z/17/Z) and the NIHR UCLH Biomedical Research Centre, UK. LW holds a GSK/British Lung Foundation Chair in Respiratory Research (C17-1). The research was partially supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre. RGJ is supported by an NIHR Research Professorship (RP-2017-08-ST2-014). AJS is a National Institute for Health Research (NIHR) Senior Investigator. Disclaimer The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Competing interests None declared.",

year = "2021",

month = sep,

day = "23",

doi = "10.1136/bmjresp-2021-001049",

language = "English",

volume = "8",

journal = "BMJ Open Respiratory Research",

issn = "2052-4439",

publisher = "BMJ Publishing Group",

number = "1",

}

UKILD-Long COVID, Wild, JM, Porter, JC, Molyneaux, PL, George, PM, Stewart, I, Allen, RJ, Aul, R, Baillie, JK, Barratt, SL, Beirne, P, Bianchi, SM, Blaikley, JF, Brooke, J, Chaudhuri, N, Collier, G, Denneny, EK, Docherty, A, Fabbri, L, Gibbons, MA, Gleeson, FV, Gooptu, B, Hall, IP, Hanley, NA, Heightman, M, Hillman, TE, Johnson, SR, Jones, MG, Khan, F, Lawson, R, Mehta, P, Mitchell, JA, Platé, M, Poinasamy, K, Quint, JK, Rivera-Ortega, P, Semple, M, Simpson, AJ, Smith, DJF, Spears, M, Spencer, LG, Stanel, SC, Thickett, DR, Thompson, AAR, Walsh, SLF, Weatherley, ND, Weeks, ME, Wootton, DG, Brightling, CE, Chambers, RC, Ho, LP, Jacob, J, Hanley, KP, Wain, LV & Jenkins, RG 2021, 'Understanding the burden of interstitial lung disease post-COVID-19: The UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)', BMJ Open Respiratory Research, vol. 8, no. 1, e001049. https://doi.org/10.1136/bmjresp-2021-001049

TY - JOUR

T1 - Understanding the burden of interstitial lung disease post-COVID-19

T2 - The UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)

AU - UKILD-Long COVID

AU - Wild, Jim M.

AU - Porter, Joanna C.

AU - Molyneaux, Philip L.

AU - George, Peter M.

AU - Stewart, Iain

AU - Allen, Richard James

AU - Aul, Raminder

AU - Baillie, John Kenneth

AU - Barratt, Shaney L.

AU - Beirne, Paul

AU - Bianchi, Stephen M.

AU - Blaikley, John F.

AU - Brooke, Jonathan

AU - Chaudhuri, Nazia

AU - Collier, Guilhem

AU - Denneny, Emma K.

AU - Docherty, Annemarie

AU - Fabbri, Laura

AU - Gibbons, Michael A.

AU - Gleeson, Fergus V.

AU - Gooptu, Bibek

AU - Hall, Ian P.

AU - Hanley, Neil A.

AU - Heightman, Melissa

AU - Hillman, Toby E.

AU - Johnson, Simon R.

AU - Jones, Mark G.

AU - Khan, Fasihul

AU - Lawson, Rod

AU - Mehta, Puja

AU - Mitchell, Jane A.

AU - Platé, Manuela

AU - Poinasamy, Krisnah

AU - Quint, Jennifer K.

AU - Rivera-Ortega, Pilar

AU - Semple, Malcolm

AU - Simpson, A. John

AU - Smith, D. J.F.

AU - Spears, Mark

AU - Spencer, Lisa G.

AU - Stanel, Stefan C.

AU - Thickett, David R.

AU - Thompson, A. A.Roger

AU - Walsh, Simon L.F.

AU - Weatherley, Nicholas D.

AU - Weeks, Mark Everard

AU - Wootton, Dan G.

AU - Brightling, Chris E.

AU - Chambers, Rachel C.

AU - Ho, Ling Pei

AU - Jacob, Joseph

AU - Hanley, Karen Piper

AU - Wain, Louise V

AU - Jenkins, R Gisli

N1 - Funding Information: The UKILD-Long COVID study is a prospective multi-centre observational cohort study that will be managed through the Imperial College National Heart and Lung Institute and funded by the UKRI Medical Research Council and an NIHR professorship (RGJ). The primary study aims to define the prevalence and risk factors for LC-ILD using data from 10 000 stratified patients, collected from the UK’s national PHOSP for COVID platform study, together with 2000 non-hospitalised patients referred for assessment up to 3 months for investigation of persistent respiratory symptoms post-COVID-19, such as breathlessness and cough (figure 1A). These patients will be recruited from Long COVID clinics or community Post-COVID-19 clinical trials (REACT Long COVID Study19). We will assess the clinical and genetic risk factors for post-COVID-19 ILD and radiological classification, as well as the trajectory and pathogenic mechanisms of progression following acute COVID with longitudinal analysis of biomarkers and the undertaking of two substudies (figure 1B). 1. Up to 80 participants will undergo detailed longitudi-nal xenon and proton MRI coupled with measures of flow-mediated endothelial function in the microvascu-lature measured by EndoPat. 2. Up to 50 participants will undergo bronchoscopy with bronchoalveolar lavage (BAL) for single cell and/or bulk RNA sequencing (RNA-seq), with matched flow cytometry analysis, as well as microbiome analysis. Funding The collaborative research programme entitled, The UK Interstitial Lung Disease-Long COVID-19 study (UKILD-Long COVID): understanding the burden of Interstitial Lung Disease in Long COVID is funded by UK Research and Innovation MRC research grant award (grant reference MR/W006111/1). The collaborative research programme entitled PHOSP-COVID Posthospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes is jointly funded by UK Research and Innovation and National Institute of Health Research (grant references: MR/V027859/1 and COV0319 and ISRCTN number 10980107). In addition, PM is supported by MRC—GlaxoSmithKline GSK Experimental Medicine and co-funding NIHR University College London Hospitals Biomedical Research Centre. JB is supported by MRC transition award (MR/ T032529/1). BG is funded by MRC-UK, the British Lung Foundation, The Alpha-1 Foundation and supported by the NIHR Leicester Biomedical Research Centre. IPH is supported by an NIHR Senior Investigator Award. SRJ is supported by Nottingham NIHR BRC. PLM is supported by an Action for Pulmonary Fibrosis Mike Bray fellowship. AART is supported by a British Heart Foundation Intermediate Clinical Fellowship (FS/18/13/3328). L-PH is supported by the NIHR Oxford Biomedical Research Centre. JJ is supported by a Wellcome Trust Clinical Research Career Development Fellowship (209553/Z/17/Z) and the NIHR UCLH Biomedical Research Centre, UK. LW holds a GSK/British Lung Foundation Chair in Respiratory Research (C17-1). The research was partially supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre. RGJ is supported by an NIHR Research Professorship (RP-2017-08-ST2-014). AJS is a National Institute for Health Research (NIHR) Senior Investigator. Disclaimer The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Competing interests None declared.

PY - 2021/9/23

Y1 - 2021/9/23

N2 - Introduction The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness and fatigue whether hospitalised or not. Early data suggest potentially severe long-term consequence of COVID-19 is development of long COVID-19-related interstitial lung disease (LC-ILD). Methods and analysis The UK Interstitial Lung Disease Consortium (UKILD) will undertake longitudinal observational studies of patients with suspected ILD following COVID-19. The primary objective is to determine ILD prevalence at 12 months following infection and whether clinically severe infection correlates with severity of ILD. Secondary objectives will determine the clinical, genetic, epigenetic and biochemical factors that determine the trajectory of recovery or progression of ILD. Data will be obtained through linkage to the Post-Hospitalisation COVID platform study and community studies. Additional substudies will conduct deep phenotyping. The Xenon MRI investigation of Alveolar dysfunction Substudy will conduct longitudinal xenon alveolar gas transfer and proton perfusion MRI. The POST COVID-19 interstitial lung DiseasE substudy will conduct clinically indicated bronchoalveolar lavage with matched whole blood sampling. Assessments include exploratory single cell RNA and lung microbiomics analysis, gene expression and epigenetic assessment. Ethics and dissemination All contributing studies have been granted appropriate ethical approvals. Results from this study will be disseminated through peer-reviewed journals. Conclusion This study will ensure the extent and consequences of LC-ILD are established and enable strategies to mitigate progression of LC-ILD.

AB - Introduction The COVID-19 pandemic has led to over 100 million cases worldwide. The UK has had over 4 million cases, 400 000 hospital admissions and 100 000 deaths. Many patients with COVID-19 suffer long-term symptoms, predominantly breathlessness and fatigue whether hospitalised or not. Early data suggest potentially severe long-term consequence of COVID-19 is development of long COVID-19-related interstitial lung disease (LC-ILD). Methods and analysis The UK Interstitial Lung Disease Consortium (UKILD) will undertake longitudinal observational studies of patients with suspected ILD following COVID-19. The primary objective is to determine ILD prevalence at 12 months following infection and whether clinically severe infection correlates with severity of ILD. Secondary objectives will determine the clinical, genetic, epigenetic and biochemical factors that determine the trajectory of recovery or progression of ILD. Data will be obtained through linkage to the Post-Hospitalisation COVID platform study and community studies. Additional substudies will conduct deep phenotyping. The Xenon MRI investigation of Alveolar dysfunction Substudy will conduct longitudinal xenon alveolar gas transfer and proton perfusion MRI. The POST COVID-19 interstitial lung DiseasE substudy will conduct clinically indicated bronchoalveolar lavage with matched whole blood sampling. Assessments include exploratory single cell RNA and lung microbiomics analysis, gene expression and epigenetic assessment. Ethics and dissemination All contributing studies have been granted appropriate ethical approvals. Results from this study will be disseminated through peer-reviewed journals. Conclusion This study will ensure the extent and consequences of LC-ILD are established and enable strategies to mitigate progression of LC-ILD.

KW - bronchoscopy

KW - COVID-19

KW - interstitial fibrosis

UR - http://www.scopus.com/inward/record.url?scp=85116117032&partnerID=8YFLogxK

U2 - 10.1136/bmjresp-2021-001049

DO - 10.1136/bmjresp-2021-001049

M3 - Article

C2 - 34556492

AN - SCOPUS:85116117032

SN - 2052-4439

VL - 8

JO - BMJ Open Respiratory Research

JF - BMJ Open Respiratory Research

IS - 1

M1 - e001049

ER -

Understanding the burden of interstitial lung disease post-COVID-19: The UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Projects

Post-hospitalisation COVID-19 study: a national consortium to understand and improve long-term health outcomes (PHOSP-COVID)

Cite this